In the past week, OTLK stock has gone up by 14.84%, with a monthly gain of 21.30% and a quarterly surge of 38.63%. The volatility ratio for the week is 2.98%, and the volatility levels for the last 30 days are 3.55% for Outlook Therapeutics Inc The simple moving average for the past 20 days is 7.85% for OTLK’s stock, with a -31.83% simple moving average for the past 200 days.
Is It Worth Investing in Outlook Therapeutics Inc (NASDAQ: OTLK) Right Now?
The stock has a 36-month beta value of 0.30. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for OTLK is 21.22M, and at present, short sellers hold a 15.17% of that float. On June 25, 2025, the average trading volume of OTLK was 541.07K shares.
OTLK) stock’s latest price update
The stock price of Outlook Therapeutics Inc (NASDAQ: OTLK) has jumped by 9.65 compared to previous close of 1.77. Despite this, the company has seen a gain of 14.84% in its stock price over the last five trading days. globenewswire.com reported 2025-06-18 that ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a Virtual Investor Lunch Break Event on Wednesday, June 25, 2025 at 12:00 PM ET.
Analysts’ Opinion of OTLK
BTIG Research, on the other hand, stated in their research note that they expect to see OTLK reach a price target of $50. The rating they have provided for OTLK stocks is “Buy” according to the report published on March 27th, 2024.
Chardan Capital Markets gave a rating of “Buy” to OTLK, setting the target price at $3 in the report published on February 15th of the previous year.
OTLK Trading at 16.90% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.02% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OTLK starting from KENYON LAWRENCE A, who purchase 5,000 shares at the price of $5.69 back on Sep 26 ’24. After this action, KENYON LAWRENCE A now owns 5,946 shares of Outlook Therapeutics Inc, valued at $28,446 using the latest closing price.
Stock Fundamentals for OTLK
The total capital return value is set at 0.0.
Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -100.78. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -0.0.
Currently, EBITDA for the company is -71.59 million with net debt to EBITDA at -449064.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.72.
Conclusion
To sum up, Outlook Therapeutics Inc (OTLK) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
